BeOne Medicines (NASDAQ:ONC – Get Free Report) is one of 896 public companies in the “Pharmaceuticals” industry, but how does it contrast to its peers? We will compare BeOne Medicines to related companies based on the strength of its risk, analyst recommendations, earnings, profitability, valuation, dividends and institutional ownership.
Institutional and Insider Ownership
48.5% of BeOne Medicines shares are owned by institutional investors. Comparatively, 32.6% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 6.2% of BeOne Medicines shares are owned by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Analyst Ratings
This is a summary of recent ratings for BeOne Medicines and its peers, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BeOne Medicines | 0 | 1 | 16 | 0 | 2.94 |
| BeOne Medicines Competitors | 7798 | 13891 | 25784 | 1038 | 2.41 |
BeOne Medicines presently has a consensus price target of $434.79, suggesting a potential upside of 4.89%. As a group, “Pharmaceuticals” companies have a potential upside of 24.75%. Given BeOne Medicines’ peers higher probable upside, analysts plainly believe BeOne Medicines has less favorable growth aspects than its peers.
Profitability
This table compares BeOne Medicines and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BeOne Medicines | 13.86% | 19.04% | 10.70% |
| BeOne Medicines Competitors | -2,380.39% | -218.78% | -15.59% |
Earnings & Valuation
This table compares BeOne Medicines and its peers gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| BeOne Medicines | $6.61 billion | $286.93 million | 52.67 |
| BeOne Medicines Competitors | $5.34 billion | $3.21 billion | 553.88 |
BeOne Medicines has higher revenue, but lower earnings than its peers. BeOne Medicines is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Volatility and Risk
BeOne Medicines has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500. Comparatively, BeOne Medicines’ peers have a beta of -3.71, suggesting that their average share price is 471% less volatile than the S&P 500.
Summary
BeOne Medicines beats its peers on 8 of the 13 factors compared.
About BeOne Medicines
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.
Receive News & Ratings for BeOne Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeOne Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
